We love progress!!!
In 2011-2012 Emmanuelle Meuillet, PhD, received a Hirshberg Seed Grant to study novel therapeutics for the treatment of pancreatic cancer. Her completed and published article “Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells” earned the Best Publication Award by the Metabolomics Society and Springer, both respected medical publishers.
The award winning work clarifies Metformin’s cancer preventing mechanism that involves ketogenic deuterium depletion. Dr. László G. Boros, Professor of Pediatrics at UCLA, one of the corresponding authors along with Dr. Mary Jo Cantori and Dr. Emmanuelle J. Meuillet, Principal Investigator, accepted the award on July 2, 2015 in San Francisco. Metformin is a low cost drug given to diabetes patients which can be used as a more cost effective alternative to prevent pancreatic cancer in obese and diabetic patients. We thank the team for the direction towards natural preventative treatments without side effects.
Congratulations to all!
Read full article: Medical News Today – Heavy Hydrogen Cancer Drugs
Read full article: Published Meuillet
